SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001; 27: 165176.
  • 2
    McCloskey EV,Guest JF,Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs. 2001; 61: 12531274.
  • 3
    Aydinli U,Ozturk C,Bayram S,Sarihan S,Evrensel T,Yilmaz HS. Evaluation of lung cancer metastases to the spine. Acta Orthop Belg. 2006; 72: 592597.
  • 4
    Cai Y,Wang WL,Xu B,Zhu GY,Zhang SW. Survival status of stage IV nonsmall cell lung cancer patients after radiotherapy—a report of 287 cases [in Chinese]. Ai Zheng. 2006; 25: 14191422.
  • 5
    Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006; 12 ( suppl): 6243s6249s.
  • 6
    DePuy V,Anstrom KJ,Castel LD,Schulman KA,Weinfurt KP,Saad F. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007; 15: 869876.
  • 7
    Major PP,Cook R. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints. Am J Clin Oncol. 2002; 25( suppl 1): S10S18.
  • 8
    Weinfurt KP,Castel LD,Li Y,Timbie JW,Glendenning GA,Schulman KA. Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care. 2004; 42: 164175.
  • 9
    Saad F,Lipton A,Cook R,Chen Y-M,Smith M,Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer. 2007; 110: 18601867.
  • 10
    Oefelein MG,Ricchiuti V,Conrad W,Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol. 2002; 168: 10051007.
  • 11
    Costa L,Demers LM,Gouveia-Oliveira A, et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol. 2002; 20: 850856.
  • 12
    Lipton A,Costa L,Ali SM,Demers LM. Bone markers in the management of metastatic bone disease. Cancer Treat Rev. 2001; 27: 181185.
  • 13
    Brown JE,Cook RJ,Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005; 97: 5969.
  • 14
    Green JR. Bisphosphonates: preclinical review. Oncologist. 2004; 9( suppl 4): 313.
  • 15
    Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer. 2002; 94: 25212533.
  • 16
    Vinholes JJF,Purohit OP,Abbey ME,Eastell R,Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol. 1997; 8: 12431250.
  • 17
    Lipton A,Demers L,Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer. 1998; 34: 20212026.
  • 18
    Pectasides D,Nikolaou M,Farmakis D, et al. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid. Anticancer Res. 2005; 25: 14571463.
  • 19
    Lipton A. Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs. 2003; 8: 469488.
  • 20
    Saad F,Gleason D,Murray R, et al. Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases [abstract]. Presented at: the XIXth Congress of the European Association of Urology; March 24-27, 2004; Vienna, Austria. Abstract 615.
  • 21
    Lipton A,Zheng M,Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003; 98: 962969.
  • 22
    Rosen LS,Gordon D,Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J. 2001; 7: 377387.
  • 23
    Rosen LS,Gordon D,Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003; 98: 17351744.
  • 24
    Rosen LS,Gordon D,Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100: 26132621.
  • 25
    Rosen LS,Gordon D,Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial—the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003; 21: 31503157.
  • 26
    Saad F,Gleason DM,Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94: 14581468.
  • 27
    Saad F,Gleason DM,Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004; 96: 879882.
  • 28
    Coleman RE,Major P,Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005; 23: 49254935.
  • 29
    Chesnut CH3rd,Bell NH,Clark GS, et al. Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med. 1997; 102: 2937.
  • 30
    Lipton A,Cook RJ,Major P,Smith MR,Coleman RE. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist. 2007; 12: 10351043.
  • 31
    Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol. 2007; 34( suppl 4): S11S16.
  • 32
    Santini D,Vincenzi B,Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res. 2007; 13: 44824486.
  • 33
    Mystakidou K,Katsouda E,Parpa E,Kelekis A,Galanos A,Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol. 2005; 22: 195201.
  • 34
    Guise TA,Mundy GR. Cancer and bone. Endocr Rev. 1998; 19: 1854.
  • 35
    Saad F,Gleason D,Chen Y-M,Eastham J. Administration of zoledronic acid before the onset of bone pain may be more effective in patients with bone metastases from prostate cancer [abstract]. Cancer Treat Rev. 2006; 32( suppl): S33. Abstract 71.
  • 36
    Costa L,Chen Y-M. Breast cancer patients without pain are at risk for skeletal-related events and may have better outcomes with zoledronic acid compared with pamidronate [abstract]. Breast Cancer Res Treat. 2006; 100( suppl): S62. Abstract 1071.